Basiliximab
Top View
- 4 Chimeric and Humanized Antibodies Have a Longer Circulating Half-Life and Reduced Immunogenicity [Adair, F 2002]. 1.5 Objectiv
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- REALLY ESSENTIAL MEDICAL IMMUNOLOGY Arthur Rabson, Ivan M.Roitt, Peter J
- Medications That Are Immunosuppressive Or Immunomodulatory (This List Is Not All-Inclusive)
- And Biomarker-Based Algorithm for Management of Acute Gvhd
- Long-Term Follow-Up of Corticosteroid Refractory Acute GVHD Treated with an Inolimomab-Based Algorithm: a Single Center Experience
- Medication Guidelines for Solid Organ Transplants
- Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
- Vaccination in Immunocompromised Patients ´Biologicals´
- Simulect® (Basiliximab)
- Immunology; an Illustrated Outline; Sixth Edition
- Provider Procedures Manual January 2019 Provider Handbooks
- Appendix A: Dosing Regimens Modelled
- Simulect, INN- Basiliximab
- Structural Basis of Immunosuppression by the Therapeutic Antibody Daclizumab
- Antivirals for Herpes Simplex Virus